当前位置: X-MOL 学术J. Parkinson’s Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Clinical Progression of Parkinson's Disease: Insights from the NINDS Common Data Elements.
Journal of Parkinson’s Disease ( IF 4.0 ) Pub Date : 2020-04-30 , DOI: 10.3233/jpd-201932
Mechelle M Lewis 1, 2 , Elias Harkins 1 , Eun-Young Lee 1 , Christy Stetter 3 , Bethany Snyder 1 , Tyler Corson 1 , Guangwei Du 1 , Lan Kong 3 , Xuemei Huang 1, 2, 4, 5, 6
Affiliation  

Background/Objective:To synchronize data collection, the National Institute of Neurological Disorders and Stroke (NINDS) recommended Common Data Elements (CDEs) for use in Parkinson’s disease (PD) research. This study delineated the progression patterns of these CDEs in a cohort of PD patients. Methods:One hundred-twenty-five PD patients participated in the PD Biomarker Program (PDBP) at Penn State. CDEs, including MDS-Unified PD Rating Scales (UPDRS)-total, questionnaire-based non-motor (-I) and motor (-II), and rater-based motor (-III) subscales; Montreal Cognitive Assessment (MoCA); Hamilton Depression Rating Scale (HDRS); University of Pennsylvania Smell Identification Test (UPSIT); and PD Questionnaire (PDQ-39) were obtained at baseline and three annual follow-ups. Annual change was delineated for PD or subgroups [early = PDE, disease duration (DD) <1 y; middle = PDM, DD = 1–5 y; and late = PDL, DD > 5 y] using mixed effects model analyses. Results:UPDRS-total, -II, and PDQ-39 scores increased significantly, and UPSIT decreased, whereas UPDRS-I, -III, MoCA, and HDRS did not change, over 36 months in the overall PD cohort. In the PDE subgroup, UPDRS-II increased and UPSIT decreased significantly, whereas MoCA and UPSIT decreased significantly in the PDM subgroup. In the PDL subgroup, UPDRS-II and PDQ-39 increased significantly. Other metrics within each individual subgroup did not change. Sensitivity analyses using subjects with complete data confirmed these findings. Conclusion:Among CDEs, UPDRS-total, -II, PDQ-39, and UPSIT all are sensitive metrics to track PD progression. Subgroup analyses revealed that these CDEs have distinct stage-dependent sensitivities, with UPSIT for DD < 5 y, PDQ-39 for DD > 5 y, UPDRS-II for early (DD < 1) or later stages (DD > 5).

中文翻译:


帕金森病的临床进展:来自 NINDS 通用数据元素的见解。



背景/目标:为了同步数据收集,美国国家神经疾病和中风研究所 (NINDS) 建议在帕金森病 (PD) 研究中使用通用数据元素 (CDE)。这项研究描绘了一组 PD 患者中这些 CDE 的进展模式。方法:125 名 PD 患者参加了宾夕法尼亚州立大学的 PD 生物标志物计划 (PDBP)。 CDE,包括 MDS 统一 PD 评定量表 (UPDRS)-总计、基于问卷的非运动 (-I) 和运动 (-II) 以及基于评分者的运动 (-III) 子量表;蒙特利尔认知评估(MoCA);汉密尔顿抑郁量表(HDRS);宾夕法尼亚大学气味识别测试(UPSIT);和 PD 问卷 (PDQ-39) 在基线和三年的年度随访中获得。描述了 PD 或亚组的年度变化[早期 = PDE,病程 (DD) <1 y;中间 = PDM,DD = 1–5 年;和晚期 = PDL,DD > 5 y] 使用混合效应模型分析。结果:在整个 PD 队列中,36 个月内,UPDRS-total、-II 和 PDQ-39 评分显着增加,UPSIT 下降,而 UPDRS-I、-III、MoCA 和 HDRS 没有变化。在 PDE 亚组中,UPDRS-II 显着增加,UPSIT 显着下降,而 PDM 亚组中 MoCA 和 UPSIT 显着下降。在 PDL 亚组中,UPDRS-II 和 PDQ-39 显着增加。每个子组内的其他指标没有改变。使用具有完整数据的受试者进行的敏感性分析证实了这些发现。结论:在 CDE 中,UPDRS-total、-II、PDQ-39 和 UPSIT 都是跟踪 PD 进展的敏感指标。 亚组分析显示,这些 CDE 具有明显的阶段依赖性敏感性,其中 UPSIT 用于 DD < 5 年,PDQ-39 用于 DD > 5 年,UPDRS-II 用于早期 (DD < 1) 或晚期 (DD >) 5)。
更新日期:2020-06-19
down
wechat
bug